Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
04/29/2016
Trade Name:
Entocort EC
Generic Name or Proper Name (*):
budesonide
Indications Studied:
Treatment of mild to moderate active Crohn's disease in patients 8 years of age and older, and maintenance of remission in Crohn’s disease in patients ages zero to 17 years of age
Label Changes Summary:
Mild to moderate active Crohn's disease * Safety and effectiveness have been established in pediatric patients 8 to 17 years who weigh more than 25 kg for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon. * Use in this age group is supported by evidence from adequate and well controlled studies of Entocort EC in adults, with additional data from 2 clinical studies in 149 pediatric patients treated up to 8 weeks and one pharmacokinetic study in 8 pediatric patients. * Safety and effectiveness have not been established in pediatric patients less than 8 years of age. Maintenance of remission in Crohn’s disease * Safety and effectiveness have not been established in pediatric patients for the maintenance of clinical remission of mild to moderate Crohn’s disease. * An open-label study to evaluate the safety and tolerability as maintenance treatment in pediatric patients aged 5 to 17 years did not establish the safety and efficacy of maintenance of clinical remission. * Safety profile is similar to safety profile observed in adults and no new safety concerns were identified. * Systemic corticosteroids, including Entocort EC, may cause a reduction of growth velocity in pediatric patients. * Pediatric patients with Crohn’s disease have a 17% higher mean systemic exposure and cortisol suppression than adults with Crohn’s disease. *Information on dosing, safety, clinical trials and PK. *Postmarketing study.
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
Elan
NNPS:
FALSE
Therapeutic Category:
Anti-inflammatory
-
-